Veru (NASDAQ:VERU) Stock Rating Lowered by Wall Street Zen

Veru (NASDAQ:VERU) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday, Wall Street Zen reports.

A number of other research firms have also issued reports on VERU. Weiss Ratings lowered Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. Canaccord Genuity Group restated a “buy” rating and set a $25.00 price objective on shares of Veru in a research report on Thursday, June 4th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $24.50.

Veru Stock Performance

Shares of NASDAQ VERU opened at $2.53 on Friday. The stock has a fifty day moving average price of $2.50 and a two-hundred day moving average price of $2.52. The firm has a market cap of $43.14 million, a P/E ratio of -3.67 and a beta of -1.17. Veru has a 1 year low of $2.05 and a 1 year high of $7.33.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.02. On average, research analysts predict that Veru will post -1.07 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Veru

A number of institutional investors have recently bought and sold shares of the stock. FNY Investment Advisers LLC acquired a new stake in Veru during the 2nd quarter worth about $328,000. Renaissance Technologies LLC acquired a new position in shares of Veru in the first quarter worth about $153,000. Finally, Royal Bank of Canada boosted its holdings in shares of Veru by 69.3% in the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after buying an additional 5,008 shares during the period. Hedge funds and other institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc is a biopharmaceutical company focused on developing medicines for obesity, metabolic disorders and cancer. Its development programs are designed to address weight management, preservation of muscle mass during weight loss and treatment of certain hormone-sensitive cancers.

The company’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being evaluated for its potential to promote or preserve lean muscle while supporting weight loss. Veru has also developed oncology candidates, including sabizabulin, an oral microtubule disruptor studied in cancer indications, and other hormone-directed therapies.

Veru was formerly known as The Female Health Company and historically developed and commercialized the FC2 Female Condom, a female-controlled barrier contraceptive and sexually transmitted infection prevention product distributed in the United States and international markets.